In preclinical studies, matuzumab demonstrated activity in the PAXF546 xenograft model of human pancreatic cancer that expressed high levels of EGFR and demonstrated almost complete resistance to clinically available chemotherapeutic drugs (Burger et al, 2003). The gene discussed is EGFR; the disease is familial pancreatic carcinoma.